Bimatoprost

Evidence Level: L5

Predicted Indications: 10

Bimatoprost

Pharmacist Assessment Report

Bimatoprost: From Glaucoma and Ocular Hypertension to Malformation Syndrome with Odontal and/or Periodontal Component

One-Sentence Summary

Bimatoprost is a prostamide (prostaglandin F2-alpha analog) originally used to lower eye pressure in open-angle glaucoma and ocular hypertension, and to grow eyelashes in eyelash hypotrichosis. The TxGNN model’s (deep learning) top-ranked prediction is malformation syndrome with odontal and/or periodontal component, but the score comes from the model and may reflect similarities the model learned between related diseases, not biological evidence. It has 0 clinical trials and 0 publications supporting it. A different prediction in the same list, alopecia, has far stronger support (see “Better-Supported Candidate” below).

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma; ocular hypertension; eyelash hypotrichosis
Predicted New Indication	Malformation syndrome with odontal and/or periodontal component
TxGNN Prediction Score	1.0000
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, bimatoprost is a prostamide/prostaglandin F2-alpha analog. It lowers intraocular pressure and also prolongs the hair-growth (anagen) phase.

For this specific prediction, no mechanistic link could be identified. A developmental malformation syndrome involving the teeth and periodontium has no recognizable connection to prostamide pharmacology. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, so this prediction should be treated as a computational artifact until independent evidence appears.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Better-Supported Candidate: Alopecia (Rank 8)

Among the ten predicted indications, alopecia (TxGNN score 1.0000) is the only one with substantial trial evidence. It has an evidence level of L2, and its mechanism is coherent. Bimatoprost extends anagen via prostanoid receptor signalling, and eyelash hypotrichosis is already an approved use.

Key clinical trials

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01325337	Phase 2	Completed	307	Three doses of bimatoprost vs vehicle and OTC minoxidil 5% in men with androgenetic alopecia
NCT01325350	Phase 2	Completed	306	Three doses of bimatoprost vs vehicle and OTC minoxidil 2% in women with female pattern hair loss
NCT01904721	Phase 2	Completed	244	Safety and efficacy in men with androgenetic alopecia
NCT02170662	Phase 2	Completed	33	Effect of topical bimatoprost on scalp hair growth and androgen-dependent follicles
NCT01023841	Phase 4	Completed	71	Safety and efficacy for eyelash hypotrichosis in children
NCT05600673	Phase 1/2	Completed	30	Bimatoprost 0.03% plus CO2 fractional laser in alopecia areata (combination design confounds the bimatoprost effect)

Selected literature

PMID	Year	Type	Journal	Key Findings
28264599	2017	Review	Expert Opin Investig Drugs	Bimatoprost for eyelash, eyebrow and scalp alopecia
38794131	2024	Review	Pharmaceuticals (Basel)	Overview of bimatoprost from ocular use to hair growth
35278027	2022	Prospective study	Dermatol Ther	Open-label study of bimatoprost for eyelash loss in alopecia totalis/universalis
37089845	2023	Non-randomized trial	Indian Dermatol Online J	Bimatoprost vs clobetasol propionate in scalp alopecia areata

Caveat: Scalp efficacy has not been confirmed in a Phase 3 trial, and the evidence is stronger for eyelashes and eyebrows than for scalp.

Canada Market Information

DIN	Product Name
02429063	VISTITAN
02350939	LATISSE
02324997	LUMIGAN RC
02533464	ZIMED PF

All four are valid single-ingredient authorizations. Dosage form and approved-indication text were not available in the compiled data.

Safety Considerations

Contraindications flagged in the knowledge graph (graph-derived associations, not label text): liver disease, gallbladder disease, uveitis, iris disease, ciliary body disease, panuveitis, macular retinal edema, cystoid macular edema, iritis.
Drug Interactions: 66 potential interactions were identified, all with an unclassified severity level. Examples include calcitriol, phentermine, pantoprazole, morphine, metformin, omeprazole, simvastatin, prednisone, and ondansetron. Clinical significance needs to be confirmed against an authoritative interaction source.

Official warnings and contraindications from the Health Canada package insert were not retrieved. Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction has no trials, no literature, and no plausible mechanism, so it is a model artifact and not a repurposing opportunity. The lower-ranked alopecia prediction is the one worth pursuing. It has several completed Phase 2 trials, but it has no Phase 3 confirmation yet.

To proceed, the following is needed:

Re-prioritize the candidate list so that alopecia (androgenetic alopecia and female pattern hair loss) is evaluated as the lead indication, with a separate decision of “Proceed with Guardrails”.
Mechanism of action data to be added to the compiled record.
Package insert warnings and contraindications from Health Canada.
Efficacy results from the Phase 2 androgenetic alopecia trials, and a Phase 3 plan for scalp use.
A topical scalp formulation and route assessment, since the approved Canadian products are ophthalmic or eyelash products.
Review of the 66 potential drug interactions with severity classification.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.